Mecasermin (INN) (trade name Increlex) is recombinant human insulin-like
growth factor 1 (IGF-I), which is used for the long-term treatment of growth failure
Jan 6, 2017 ... Easy to read patient leaflet for mecasermin. Includes indications, proper use,
special instructions, precautions, and possible side effects.
May 16, 2007 ... Description, Mecasermin contains recombinant-DNA-engineered human insulin-
like growth factor-1 (rhIGF-1). IGF-1 consists of 70 amino acids ...
Manufacturer's information about recombinant human insulin-like growth factor-1,
marketed under the brand name Increlex (generic name mecasermin).
Listing for FDA approved drug therapies archives from CenterWatch. (
INCRELEX® (mecasermin [rDNA origin] injection) number of cases indicative of
anaphylaxis requiring hospitalization have been reported. Parents and patients ...
Number: 0711. Policy. Aetna considers mecasermin (Increlex) and mecasermin
rinfabate (Iplex)* medically necessary for the treatment of growth failure in ...
www.omedarx.com/files/Increlex, mecasermin dru126.pdf
Policy No: dru126. Topic: Increlex®, mecasermin. Date of Origin: January 3, 2006
. Committee Approval Date: January 8, 2016. Next Review Date: January 2017.
INCRELEX (mecasermin) is recombinant human insulin-like growth factor-1 ...
Mecasermin was granted orphan status in the EU for “Treatment of growth ...